$CBDW: Adnexus Biotechnologies Unveils Sutra(TM), a

New Post Public Reply Private Reply Replies (1) Message Board
Lee Adams stocksonhighalert #88853
116
$CBDW: Adnexus Biotechnologies Unveils Sutra(TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research

DALLAS, TX / ACCESSWIRE / October 1, 2024 / Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research, is pleased to announce its new AI Empowered Drug Discovery Platform, Sutra™.

https://www.accesswire.com/imagelibrary/0ba2a.../12084.png

The Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their potential from collaborators. Adnexus Biotechnologies Inc.'s AI algorithms have identified several promising drug candidates. The company has identified a target in the mitochondrial metabolism that has a role in oncology. The company then adds them to an ever-growing IP portfolio, including patents, trademarks, and trade secrets, enhancing its competitive advantage and potential for future revenue. The success and validation of the Sutra™ AI platform for AI-discovered drugs are testaments to its capabilities and the future it promises.

Adnexus Biotechnologies Inc. is dedicated to pushing the boundaries of drug discovery with its AI Drug Discovery (AIDD) player, Sutra™. With its AI-powered structure prediction algorithms, this platform has the potential to revolutionize drug discovery. It can design small molecules, optimize the design of antibodies and other proteins, and even repurpose drug molecules. With a database of 19 viruses, the Sutra™ AI platform can predict and help prevent future pandemics. With access to a curated library of 8 million molecules, the platform makes possible the discovery of new drugs that precisely target neutralizable epitopes on viruses to enhance the potency and efficacy of existing therapies. The Sutra™ team's unwavering dedication to leveraging microbiome samples to identify new biomarkers for neurodegenerative diseases instills hope for future medical breakthroughs.

Adnexus Biotechnologies Inc. harnesses the power of AI to revolutionize drug repurposing, offering a cost-effective alternative to developing new drugs from the ground up. Drug repurposing involves identifying potential new applications for existing compounds, which can be time-consuming and labor-intensive. However, AI algorithms can analyze existing drug databases and identify potential new applications for these compounds in a fraction of the time, making it a game-changer in the pharmaceutical industry. Adnexus is exploring synergizing AI with suitable linkers between antibodies and drugs to promote multi-drug combinations. This approach will bring new therapeutics to market with more substantial impacts than combination therapies and address unmet medical needs, expediting drug discovery and regulatory approvals.

Gaurav Chandra, the CEO of Adnexus Biotechnologies Inc., stated, "Our innovative use of AI reflects a broader trend toward embracing advanced technologies to overcome traditional limitations in the biotech industry. We are very excited about our AI-empowered drug discoveries. Adnexus is proud to introduce and implement the latest Artificial Intelligence innovations in research and development technology-keeping the company at the forefront of early drug discovery and development and other revolutionary discoveries critical to treating infectious diseases."

Dr. Chandra continued, "As we advance our HIV therapeutics, we intend to offer our expertise as unique SAAS and DAAS revenue-generating models by next year. This strategic move is part of our commitment to pursuing multiple revenue-generating strategies to broaden our offerings and support academic and biotechnology companies in advancing their scientific endeavors. This commitment underscores our financial stability and growth potential."

Adnexus has recently executed a Letter of Intent with 1606 Corp (OTC PINK:CBDW), an AI technology company, for a strategic investment in the company.

About Adnexus Biotechnologies Inc.

Adnexus is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease, and neurodegenerative disease research. Its proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. For more information, please visit https://www.adnexusbiotech.com.

Industry Information

The global market size for artificial intelligence in drug discovery was estimated at USD 1.5 billion in 2023 and is projected to grow at a CAGR of 29.7% from 2024 to 2030. The demand for AI-powered solutions in drug discovery is increasing due to the need for new drug therapies, expanded manufacturing capacities in the life sciences industry, and technological advancements. AI technologies such as machine learning and deep learning are being used at various stages of drug discovery, including initial compound screening and predicting success rates in clinical trials. Additionally, the growth of startups developing AI-powered solutions and increased investments and funding drive market expansion.

Forward-Looking Statements

This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. Adnexus does not undertake any obligation to update forward-looking statements except as required by law.

For inquiries, please get in touch with Dr. Gaurav Chandra, CEO, gaurav.chandra@adnexusbiotech.com.

https://www.adnexusbiotech.com

http://www.cbdw.ai

Contact Information

Gaurav Chandra
CEO
gaurav.chandra@adnexusbiotech.com

SOURCE: Adnexus Biotechnologies Inc.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DJI Puts 3D Conservation Tools to Work Across Segovia

Updated Category News Views 59

Stone monuments do not care about marketing slogans; they care whether somebody notices the crack before winter gets hold of it. That is why DJI’s World Heritage 3D Conservation Initiative in Segovia lands as more than a shiny drone-company ceremony. The company gathered winning 3D fly-through work from its first initiative, but the useful bit was the case for turning...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 143

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 16

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 70

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 114

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 47

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 122

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 64

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading

Top 5 Most Recently Viewed Articles

FirstEnergy Reports Strong Q3 2024 Financial Outcomes

Updated Category News Views 232

Strong Third Quarter Earnings Performance FirstEnergy Corp. recently revealed impressive financial results for the third quarter of 2024, showcasing GAAP earnings from continuing operations at $419 million. This translates to earnings per share of $0.73, demonstrating slight retention from the previous year's earnings of $421 million, which were $0.74 per share on...

Continue Reading
Apple Delays Apple Intelligence in EU Over DMA Concerns

Updated Category Business Views 583

Apple Delays Launch of Apple Intelligence in EU Due to Regulatory Hurdles The European Union launch of Apple Intelligence AI product will be delayed, the company said. The "regulatory uncertainties" pertaining to the Digital Markets Act (DMA) of the EU are the cause of the delay. Apple voiced worries that the DMA might jeopardize the quality of their offerings. Keeping...

Continue Reading
AMVital Turmeric Soap Achieves Top Sales and Customer Satisfaction

Updated Category News Views 219

AMVital Turmeric Soap Surges in Popularity AMVital, a prominent name in turmeric skincare, has made waves in the beauty market. Their Turmeric Kojic Acid Soap Bar recently secured the top spot on Walmart Marketplace, outpacing competitors and earning substantial consumer trust. Exceptional Customer Feedback This innovative soap has amassed over 13,000 verified reviews...

Continue Reading
ChemoMetec Expands Its Portfolio with Ovizio Acquisition

Updated Category News Views 90

ChemoMetec Acquires Ovizio Imaging Systems SA ChemoMetec has taken an important step by submitting a binding tender offer for the complete acquisition of Belgian company Ovizio Imaging Systems SA. This decision comes after careful consideration and a thorough due diligence process. Details of the Acquisition The acquisition is set at a price of EUR 2,830,000. Exciting...

Continue Reading
Tether's Vision: Dirham-Pegged Stablecoin and More

Updated Category News Views 135

Tether's New Dirham-Pegged Stablecoin Initiative During a recent interview, Tether CEO Paolo Ardoino provided valuable insights about the company’s latest developments. One of the key announcements was the upcoming launch of a stablecoin pegged to the UAE's currency, the Dirham. The introduction of this stablecoin reflects Tether's commitment to adapting to the evolving...

Continue Reading